A Phase 3 interventional study of DTaP-IPV-HB-PRP~T combined vaccine and DTaP-IPV//PRP~T combined vaccine in Haemophilus Influenzae Type b Immunisation, Hepatitis B Immunisation and Polio Immunization, sponsored by Sanofi. Not yet recruiting. Open to participants aged 30 Days to 45 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Sanofi · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Diphtheria by Sanofi — 1 open to participants now, 1 under way, 1 of them phase 3. Diphtheria · Sanofi.
Among the 81 studies in Diphtheria by Sanofi, this one is the 32nd largest by planned enrollment of the 75 interventional ones that give a count, is the only one that started in 2026, is one of 46 in phase 3, and was the 81st registered.
268 studies on the registry are indexed under Diphtheria; 18 are open to participants now.
Browse Diphtheria studies →1 of the 81 studies in Diphtheria by Sanofi is open now.
Of the 11 Diphtheria studies recruiting now, 2 (18%) set no upper age limit and 9 (82%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.
This study: 30 Days to 45 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 46 · Phase 4 20
First in 1999; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 720 is above the median of 449 across 242 interventional studies indexed under Diphtheria.
Median enrollment 600 across the 75 interventional studies, 5,185 across the 6 observational. Of the 80 that completed or were terminated, 46 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 81 studies in Diphtheria by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure the safety and immunogenicity of Hexaxim given at 2, 4, and 6 MoA compared with Pentaxim given at 2, 4, and 6 MoA plus a monovalent Hep B vaccine given at 1 and 6 MoA in healthy Chinese infants born to HBsAg seronegative mothers.
Study details include:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hexaxim at 2, 4 and 6 MoA
Biological: DTaP-IPV-HB-PRP~T combined vaccine
Pentaxim at 2, 4, 6, and 18 MoA, and the monovalent Hepatitis B vaccine at 1 and 6 MoA
Biological: DTaP-IPV//PRP~T combined vaccine · Biological: monovalent Hep B vaccine
Pharmaceutical form:Suspension for injection in a pre-filled syringe Route of administration:IM injection
Pharmaceutical form:Freeze-dried PRP\~T in a vial reconstituted with the injectable suspension of DTaP-IPV in a pre-filled syringe Route of administration:IM injection
Pharmaceutical form: Depending on the brand procured Route of administration:IM injection
1 month after the last dose of primary series (investigational group [Hexaxim: Group 1] and comparator group [Pentaxim and monovalent Hep B: Group 2]) (7 MoA):
Anti-D Ab concentrations ≥0.1 IU/mL Anti-T Ab concentrations ≥0.1 IU/mL Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil) Anti-PRP Ab concentrations ≥0.15 µg/mL Seroconversion for anti-PT and anti-FHA, defined as anti-PT and anti-FHA ≥4-fold Ab concentrations increase from pre-Dose 1 to 1 month post-Dose 3 Anti-Hep B Ab concentrations ≥10 mIU/mL GMC of PT and FHA
Time frame: Day181
Baseline, pre-vaccination sample
Ab concentrations/titers for each Ag Ab concentrations/titers above a cut-off: * Anti-D Ab concentrations ≥0.01 IU/mL and ≥0.1 IU/mL * Anti-T Ab concentrations ≥0.01 IU/mL and ≥0.1 IU/mL * Anti-PRP Ab concentrations ≥0.15 μg/mL * Anti-Hep B Ab concentrations ≥10 mIU/mL * Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil)
Time frame: Day 31
1 month after the last dose of primary series:
Ab concentrations/titers for each Ag Ab concentrations/titers above a cut-off: * Anti-D Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL * Anti-T Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL * Anti-PRP Ab concentrations ≥0.15 μg/mL and ≥1.0 μg/mL * Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil) * Anti-Hep B Ab concentrations ≥10 mIU/mL and ≥100 mIU/mL Ab individual concentration/titer ratios for all antigens except for Hep B) (post-Dose 3/pre-Dose 1) Anti-Hep B Ab individual concentration ratio (post-Dose 4 Hep B/pre-Dose 2 Hep B in the investigational group, or post-Dose 3 Hep B/post-Dose 2 Hep B in the comparator group) Note: Dose 1 Hep B corresponds to the dose of Hep B vaccine given at birth.
Time frame: Day181
Before the booster dose:
Ab concentrations/titers for each Ag of Pentaxim and Hep B Ab concentrations/titers above a cut-off: * Anti-D Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL * Anti-T Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL * Anti-PRP Ab concentrations ≥0.15 mg/mL and ≥1.0 mg/mL * Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil) * Anti-Hep B Ab concentrations ≥10 mIU/mL and ≥100 mIU/mL
Time frame: Day 511
1 month after the booster dose:
Ab concentrations/titers for each Ag of Pentaxim Ab concentrations/titers above a cut-off: * Anti-D Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL * Anti-T Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL * Anti-PRP Ab concentrations ≥0.15 mg/mL and ≥1.0 mg/mL * Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil) Seroconversion for anti-PT and anti-FHA defined as anti-PT and anti-FHA ≥4-fold Ab concentrations increase from pre-Booster to post-Booster Ab individual concentration/titer ratios for all antigens (post-Booster/pre-Booster)
Time frame: Day 541
Presence of immediate unsolicited adverse events (AEs)
Time frame: 30 minutes after each and any vaccination
Presence of solicited injection site reactions
(pre-listed in the participant diary and case report form \[CRF\])
Time frame: for 8 days, including the day of each and any vaccination
Presence of solicited systemic reactions
(pre-listed in the participant diary and CRF)
Time frame: for 8 days, including the day of each and any vaccination
Presence of unsolicited AEs
Time frame: for 30 days, including the day of each and any vaccination
Presence of serious adverse events (SAEs)
Time frame: up to 12 months post last dose of vaccination in the primary series, and up to 1 month post booster vaccination
Presence of related SAEs and fatal case regardless of causality
Time frame: Day 541
Presence of AEs leading to study discontinuation
Time frame: Day 541
No study locations are listed for this record.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Apr 2028, 15 months later.
Of 47 industry-sponsored phase 3 interventional studies under Diphtheria, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 21. This study's planned 15 months is above that.
Counting every sponsor, half of 47 studies reached it within 13 months; a quarter within 7 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.